The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Japan Hails Janssen Vaccine Submission as New Option: Spokesman
Chief Cabinet Secretary Katsunobu Kato on May 24 welcomed the Japanese regulatory submission of Janssen Pharmaceutical’s single-dose COVID-19 vaccine earlier in the day, which will increase options to fight the lingering pandemic in Japan, if approved. “I believe swift reviews…
To read the full story
Related Article
- Janssen Seeks Japan Approval for COVID-19 Vaccine
May 24, 2021
- Janssen Resumes Japan PI for COVID-19 Vaccine after Temporary Pause
November 17, 2020
- J&J Pauses COVID-19 Vaccine Trials, Japan PI Too
October 14, 2020
- Janssen Launches Japan PI Study for Coronavirus Vaccine
September 2, 2020
REGULATORY
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…